{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:20Z","timestamp":1794414440697,"version":"4.9.1"},"reference-count":51,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:sec id=\"ab-hsc260001-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Clonal hematopoiesis of indeterminate potential (CHIP) has emerged as an independent and potent cardiovascular risk factor. As genetic sequencing becomes more widespread and the population ages, the identification of CHIP will increase substantially. Despite strong epidemiologic and mechanistic evidence linking CHIP to cardiovascular disease, no randomized trials have prospectively addressed this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hsc260001-2\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine the major challenges in designing cardiovascular outcomes trials in CHIP and to propose a road map for advancing the evidence base for potential CHIP-targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hsc260001-3\">\n                    <jats:title>Evidence Review<\/jats:title>\n                    <jats:p>This Special Communication synthesizes current epidemiologic, mechanistic, and clinical considerations relevant to cardiovascular trial design in CHIP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hsc260001-4\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Multiple challenges complicate the design of cardiovascular outcomes trials in CHIP. Genetic heterogeneity across CHIP driver mutations leads to distinct biological mechanisms and cardiovascular outcomes, complicating end point selection. Cardiovascular risk also varies by clone size, creating trade-offs between broad eligibility and adequate event rates and statistical power. Differences in sequencing platforms and detection thresholds further hinder consistent risk stratification and reproducibility. Moreover, limited access to genetic testing impedes timely identification and enrollment of eligible participants. Finally, ethical concerns related to screening asymptomatic individuals, along with the advanced age and comorbidity burden of many CHIP carriers, pose challenges to recruitment, retention, and trial feasibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hsc260001-5\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Designing cardiovascular outcomes trials in CHIP will require moving beyond a 1-size-fits-all approach toward genotype-informed, mechanism-driven trial frameworks. Leveraging innovative trial designs, integrating CHIP analyses into ongoing cardiovascular trials, and fostering interdisciplinary multicenter collaboration will accelerate translating CHIP biology into effective cardiovascular therapies. Establishing an evidence base for managing CHIP-associated cardiovascular risk represents a critical and timely priority for precision cardiovascular medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.3593","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:28Z","timestamp":1788966028000},"page":"1139","source":"Crossref","is-referenced-by-count":1,"title":["Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis of Indeterminate Potential"],"prefix":"10.1001","volume":"11","author":[{"given":"Nicholas","family":"Chiu","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Heart and Vascular Institute at Mass General Brigham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Oren","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeron M.","family":"Small","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Heart and Vascular Institute at Mass General Brigham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachelle D.","family":"Weeks","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Marston","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Heart and Vascular Institute at Mass General Brigham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Honigberg","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Heart and Vascular Institute at Mass General Brigham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Heart and Vascular Institute at Mass General Brigham, Boston, Massachusetts"},{"name":"Heart and Vascular Institute, Center of Excellence in Vascular Biology and Center for Inflammation Imaging at Mass General Brigham Hospital and the Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"26","key":"hsc260001r1","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes.","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"hsc260001r2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms.","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"hsc260001r3","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"hsc260001r4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"7939","key":"hsc260001r5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41586-022-05448-9","article-title":"Common and rare variant associations with clonal haematopoiesis phenotypes.","volume":"612","author":"Kessler","year":"2022","journal-title":"Nature"},{"issue":"9","key":"hsc260001r6","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1038\/s41591-024-03188-z","article-title":"Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials.","volume":"30","author":"Marston","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"hsc260001r7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41569-025-01148-9","article-title":"Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target.","volume":"22","author":"Schuermans","year":"2025","journal-title":"Nat Rev Cardiol"},{"issue":"7831","key":"hsc260001r8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes.","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"issue":"2","key":"hsc260001r9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/bjh.19925","article-title":"A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis.","volume":"206","author":"Haque","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"hsc260001r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.51927","article-title":"Clonal hematopoiesis risk score and all-cause and cardiovascular mortality in older adults.","volume":"7","author":"Saadatagah","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"hsc260001r11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s44161-022-00206-6","article-title":"TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease.","volume":"2","author":"Zekavat","year":"2023","journal-title":"Nat Cardiovasc Res"},{"issue":"20","key":"hsc260001r12","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.jacc.2023.03.401","article-title":"Clonal hematopoiesis of indeterminate potential predicts adverse outcomes in patients with atherosclerotic cardiovascular disease.","volume":"81","author":"Gumuser","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"hsc260001r13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1182\/blood.2022017661","article-title":"Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke.","volume":"141","author":"Arends","year":"2023","journal-title":"Blood"},{"issue":"2","key":"hsc260001r14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis.","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"issue":"9","key":"hsc260001r15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s44161-023-00326-7","article-title":"Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypes.","volume":"2","author":"Rauch","year":"2023","journal-title":"Nat Cardiovasc Res"},{"issue":"1","key":"hsc260001r16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41467-023-43003-w","article-title":"DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts.","volume":"15","author":"Shumliakivska","year":"2024","journal-title":"Nat Commun"},{"issue":"6327","key":"hsc260001r17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"issue":"3","key":"hsc260001r18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCRESAHA.118.313225","article-title":"CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease.","volume":"123","author":"Sano","year":"2018","journal-title":"Circ Res"},{"issue":"22","key":"hsc260001r19","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1161\/CIRCULATIONAHA.124.072909","article-title":"TET2-mutant clonal hematopoiesis promotes heart failure with preserved ejection fraction.","volume":"151","author":"Pandey","year":"2025","journal-title":"Circulation"},{"issue":"18","key":"hsc260001r20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168597","article-title":"Genetic modification of inflammation- and clonal hematopoiesis-associated cardiovascular risk.","volume":"133","author":"Yu","year":"2023","journal-title":"J Clin Invest"},{"issue":"436","key":"hsc260001r21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"issue":"7853","key":"hsc260001r22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41586-021-03341-5","article-title":"The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis.","volume":"592","author":"Fidler","year":"2021","journal-title":"Nature"},{"issue":"19","key":"hsc260001r23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180066","article-title":"Clonal hematopoiesis and atherosclerosis.","volume":"134","author":"Oren","year":"2024","journal-title":"J Clin Invest"},{"issue":"6","key":"hsc260001r24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jamacardio.2024.0459","article-title":"Atrial fibrillation and clonal hematopoiesis in TET2 and ASXL1.","volume":"9","author":"Saadatagah","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"11","key":"hsc260001r25","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/CIRCRESAHA.118.313283","article-title":"Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 V617F mice.","volume":"123","author":"Wang","year":"2018","journal-title":"Circ Res"},{"issue":"1","key":"hsc260001r27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"3","key":"hsc260001r28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/eurheartj\/ehaa845","article-title":"Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.","volume":"42","author":"Assmus","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"hsc260001r29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure.","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"1","key":"hsc260001r30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jacc.2021.04.085","article-title":"Supplemental association of clonal hematopoiesis with incident heart failure.","volume":"78","author":"Yu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"hsc260001r31","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1182\/bloodadvances.2024013228","article-title":"Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis.","volume":"8","author":"Singh","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"hsc260001r32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jamacardio.2023.5095","article-title":"Somatic and germline variants and coronary heart disease in a Chinese population.","volume":"9","author":"Zhao","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"10","key":"hsc260001r33","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1038\/s41591-024-03213-1","article-title":"Unidirectional association of clonal hematopoiesis with atherosclerosis development.","volume":"30","author":"D\u00edez-D\u00edez","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"hsc260001r34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI198861","article-title":"Detection of clonal hematopoiesis of indeterminate potential via genome or exome sequencing underestimates disease associations.","volume":"136","author":"Corty","year":"2026","journal-title":"J Clin Invest"},{"issue":"1","key":"hsc260001r35","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(19)30211-X","article-title":"Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.","volume":"7","author":"Gondek","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"hsc260001r36","doi-asserted-by":"publisher","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults.","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"issue":"18","key":"hsc260001r37","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood.2022018825","article-title":"A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets.","volume":"141","author":"Vlasschaert","year":"2023","journal-title":"Blood"},{"issue":"15","key":"hsc260001r38","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.jacc.2024.06.045","article-title":"Influence of subclinical atherosclerosis burden and progression on mortality.","volume":"84","author":"Fuster","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hsc260001r39","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis.","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"issue":"6","key":"hsc260001r40","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jcct.2022.07.002","article-title":"CAD-RADS\u2122 2.0 - 2022 Coronary Artery Disease-Reporting and Data System: an expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the American College of Radiology (ACR), and the North America Society of Cardiovascular Imaging (NASCI).","volume":"16","author":"Cury","year":"2022","journal-title":"J Cardiovasc Comput Tomogr"},{"issue":"1","key":"hsc260001r41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.53244","article-title":"Clonal hematopoiesis and incident heart failure with preserved ejection fraction.","volume":"7","author":"Schuermans","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"hsc260001r42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial.","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"12","key":"hsc260001r43","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jamacardio.2025.3756","article-title":"Clonal hematopoiesis and cardiovascular disease and bleeding risk and the effectiveness of aspirin.","volume":"10","author":"McQuilten","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"21","key":"hsc260001r44","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.jacc.2025.08.025","article-title":"Colchicine and longitudinal dynamics of clonal hematopoiesis: an exploratory substudy of the LoDoCo2 trial.","volume":"86","author":"Mohammadnia","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hsc260001r48","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"hsc260001r49","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/jamacardio.2025.3744","article-title":"A new bleeding signal in clonal hematopoiesis-white cells, red flags.","volume":"10","author":"Chiu","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"6","key":"hsc260001r50","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s44161-023-00281-3","article-title":"Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis.","volume":"2","author":"Liu","year":"2023","journal-title":"Nat Cardiovasc Res"},{"issue":"16","key":"hsc260001r51","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments.","volume":"313","author":"Berry","year":"2015","journal-title":"JAMA"},{"key":"hsc260001r26","doi-asserted-by":"crossref","unstructured":"Pershad? Y, Zhao? K, Van Amburg? JC, . Mutation-specific impairment of TET2 and DNMT3A enzymatic activity predicts clonal hematopoiesis disease risk.? medRxiv. Published online April 5, 2026. doi:10.64898\/2026.04.03.26350108","DOI":"10.64898\/2026.04.03.26350108"},{"key":"hsc260001r45","unstructured":"Honigberg? MC; ClinicalTrials.gov. Effects of IL-1 beta inhibition on vascular inflammation in TET2 clonal hematopoiesis: NCT06691217. Accessed November 16, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06691217"},{"key":"hsc260001r46","unstructured":"Novartis Pharmaceuticals; ClinicalTrials.gov. A randomized, placebo-controlled, parallel-group, investigator- and participant-blinded phase 2a study to investigate the efficacy, safety, and tolerability of DFV890 and MAS825 for inflammatory marker reduction in an adult population with coronary heart disease and clonal hematopoiesis of indeterminate potential (CHIP). Accessed November 16, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06097663"},{"key":"hsc260001r47","unstructured":"Roche. A phase Ic multicenter, randomized, double-blind, placebo-controlled study to assess the safety, pharmacokinetics, and pharmacodynamics following 4 weeks of NLRP3 inhibition with selnoflast in participants with coronary artery disease. Accessed November 16, 2025. https:\/\/forpatients.roche.com\/en\/trials\/cardiovascular-disorder\/coronary-artery-disease\/a-phase-ic-multicenter--randomized--double-blind--placebo-contro.html"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2853939\/jamacardiology_chiu_2026_sc_260001_1793998738.4979.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:02:28Z","timestamp":1794412948000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2853939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.3593","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11,1]]}}}